羧酸酯酶-2和拓扑异构酶1的表达对伊立替康联合铂类治疗小细胞肺癌的预测意义初探  

Prognostic Implication of Expression of Carboxylesterase 2 and Topoisomerase 1 in Small Cell Lung Cancer with Irinotecan Combined with Platinum Treatment

作　　者：肖晓光[1] 刘东[2] 张程亮[2] 王淑静[1] 夏曙[1] 邹曼[1] 陈元[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤科,武汉430030 [2]华中科技大学同济医学院附属同济医院药学部,武汉430030

出　　处：《药物流行病学杂志》2015年第11期637-641,共5页Chinese Journal of Pharmacoepidemiology

基　　金：中央高校基本科研业务费项目(HUST:2013ZHYX013)

摘　　要：目的:探讨小细胞肺癌组织中羧酸酯酶-2(CES-2)和拓扑异构酶1(topo1)的表达对伊立替康(CPT-11)联合铂类化疗预后的临床意义。方法:分别应用免疫组化方法和酶联免疫吸附方法检测接受CPT-11联合铂类治疗的48例小细胞肺癌患者组织CES-2表达和topo1活性,并与患者化疗的临床预后如无疾病进展期(PFS)和总生存期(OS)进行比较。结果:48例小细胞肺癌标本中,CES-2阳性比为72.9%,topo1活性为(22 459±5 422)U·mg-1protein,CES-2表达及topo1活性在不同分期小细胞肺癌患者中差异均无统计学意义(P>0.05)。不同分期小细胞肺癌患者CES-2是否表达与其中位PFS及OS差异亦均无统计学意义(P>0.05)。31例局限期小细胞肺癌患者中,CES-2表达阳性的中位PFS及OS分别是12.3,18个月;CES-2表达阴性的中位PFS及OS分别是10.9,17.6个月。17例广泛期小细胞肺癌患者中,CES-2表达阳性的中位PFS及OS分别是10.5,14.1个月;CES-2表达阴性的中位PFS及OS分别是10.2,13.8个月。结论:CES-2表达和topo1活性尚不足以预测CPT-11联合铂类治疗小细胞肺癌的预后,有待扩大样本量进一步从疗效、毒性及预后方面同时考察。Objective： To explore the prognosis of expression of carboxylesterase-2（ CES-2） and topoisomerase 1（ Topo1） in small cell lung cancer（ SCLC） on irinotecan combined with platinum chemotherapy. Methods： Using the immunohistochemical and ELISA method detected the expression of human CES-2 and Topo1 respectively in 48 patients treated with irinotecan（ CPT-11） and platinum regimen,and comparison with progression-free survival（ PFS） and overall survival（ OS）. Results： Among 48 cases,the positive rate of CES-2 expression was 72. 9%,the totaltopo1 activity（ 22 459± 5 422） U·mg^- 1protein,but significant difference was not observed in CES-2 and Topo1 expression between different stages（ P 〉0. 05）. Moreover,PFS and OS in CES-2 positive or CES-2 negative patients were also not significantly different in LD-SCLC and ED-SCLC stages（ P 〉0. 05）. 31 cases with LD-SCLC,the PFS and OS of CES-2 positive expression were 12. 3 and 18 months respectively,and PFS and OS of CES-2 negative expression were 10. 9 and 17. 6 months respectively. 17 cases with ED-SCLC,the PFS and OS of CES-2 positive expression were 10. 5 and 14. 1 months respectively,and PFS and OS of CES-2 negative expression were 10. 2 and 13. 8 months respectively. Conclusion： Expression of CES-2 and Topo1 failed to predict the efficacy of CPT-11 in SCLC. It should be further study on the effect,toxicity and prognosis.

关 键 词：小细胞肺癌 羧酸酯酶-2 拓扑异构酶1 伊立替康 

分 类 号：R979.1[医药卫生—药品]